INSIGHTS ON PHARMACEUTICAL INSPECTION

PHARMACEUTICAL INSPECTION SOLUTIONS

  • The VeriPac 465 performs leak detection based on the basic principles of physics and does not require the use of trace gasses or sample preparation to perform the test. The VeriPac 465 core technology is based on the ASTM vacuum decay leak test method (F2338) recognized by the FDA as a consensus standard for package integrity testing. This test method was developed using VeriPac leak test instruments.

  • The XR75 Pharma X-ray is optimized for the quality control of pharmaceutical, nutraceutical, and cosmetic products in thin opaque packaging materials that cannot be inspected manually or with visual systems.

  • The most current model, the Seal Integrity Monitoring System (SIMS) 1915+, is the ideal choice for your helium-based leak detection system. Compared to conventional vacuum bubble and dye penetration test methods, packages can be quantitatively tested using helium as the tracer gas that ensures higher levels of accuracy. Such an approach allows a comparison between multiple packaging materials and forms production line settings and stability storage conditions, supporting the entire lifecycle.

  • Efficient, customizable, intuitive use

    Advanced bottom inspection of a variety of packages. The system supports customized lighting and can be extended with top cameras for further applications such as seal contamination inspection.

    Effective Bottom Inspection

    Supporting up to 400 ppm, capture the nuances associated with various product shapes or sizes where a larger field of view is required.

    Application Based Design

    Cameras and advanced lighting options help overcome challenging applications where wet, reflective, or uneven surfaces interfere with imaging.

    Intuitive Software

    Powerful CIVCore software offers a range of inspection options for easy setup and configuration.

  • As the governing regulatory document of the European Medicines Agency (EMA), EU GMP Annex 1 discusses a full host of concepts related to manufacture of sterile medicinal products. In contrast to guidance documents issued by the FDA, EU GMP Annex 1 is interpreted as law, requiring strict adherence to the regulatory expectations contained, numerous of which allude to container closure integrity testing. In fact, current proposed and ongoing revisions increase the expectations of scrutiny on package integrity.